ArticleClinical ophthalmology (Auckland, N.Z.)2025
Prospective Evaluation of RedTouch Laser in the Treatment of Dry Eye Disease Secondary to Meibomian Gland Dysfunction.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic efficacy and safety of a multi-wavelength LED irradiation device in a rat model of meibomian gland dysfunction.Lasers in medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To validate the efficacy of RedTouch laser, a new 675 nm laser system in treating dry eye disease (DED) secondary to Meibomian gland dysfunction (MGD), comparing generalized periocular treatment versus direct targeting of the meibomian glands. Patients and Methods: 70 patients with mild and moderate DED-MGD received 4 sessions of laser treatment separated by 3 weeks, with assessments before treatment, T0, and at the end, T1, after 2 months from the last session. Patients were divided randomly into 2 groups (G1 and G2) of 35 patients each to test different protocols. In G1, the eyelids and periocular area were treated with a 675 nm laser and G2, with the same treatment as in G1 but combined with a free pencil-shaped handpiece on the tarsal conjunctiva of the superior and inferior eyelids as well as on the lid margin of both eyelids. Results: The outcomes resulted in a significant improvement in all symptoms and signs of both groups, OSDI, CFS, NITMH, NITBUT, Osmolarity and Schirmer test1. However, G2-receiving additional targeted meibomian gland treatment-showed superior outcomes across all parameters (G1 vs G2, p < 0.001), including the signs of the Meibomian glands and the lid margin (G1 vs G2, p < 0.001). Conclusion: RedTouch laser is an effective treatment in patients with DED related to MGD, improving signs and symptoms. While periocular skin treatment alone provides clinical benefits, outcomes are significantly better when the laser is applied directly to the lid margin and tarsal conjunctiva, targeting the meibomian glands more specifically. No complications were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.